Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia

Blood

Volumn 107, Issue 11, 2006, Pages 4563-4569

  Moreno, Carol ^b   Villamor, Neus ^b   Colomer, Dolors ^b   Esteve, Jordi ^b   Giné, Eva ^b   Muntañola, Ana ^b   Campo, Elias ^b   Bosch, Francesc ^b   Montserrat, Emili ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ALLOGRAFT; ARTICLE; AUTOTRANSPLANTATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MALE; MINIMAL RESIDUAL DISEASE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RELAPSE; STEM CELL TRANSPLANTATION;

EID: 33744495070     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-09-3634     Document Type: Article

References (34)

1. Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005;23:4079-4088.
2. Wierda W, O'Brien S, Wen S, et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol. 2005;23:4070-4078.
3. Montserrat E. CLL therapy: progress at last! Blood. 2005;105:2-3.
4. Dreger P, Montserrat E. Autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemia. Leukemia. 2002;16:985-992.
5. Montserrat E. Role of auto- and allotransplantation in B-cell chronic lymphocytic leukemia. Hematol Oncol Clin North Am. 2004;18:915-926.
6. Bosch F, Ferrer A, Lopez-Guillermo A, et al. Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia. Br J Haematol. 2002;119:976-984.
7. Esteve J, Villamor N, Colomer D, Montserrat E. Different clinical value of minimal residual disease after autologous and allogenic stem cell transplantation for chronic lymphocytic leukemia. Blood. 2002;99:1873-1874.
8. Moreton P, Kennedy B, Lucas G, et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol. 2005;23:2971-2979.
9. Donovan JW, Ladetto M, Zou G, et al. Immunoglobulin heavy-chain consensus probes for real-time PCR quantification of residual disease in acute lymphoblastic leukemia. Blood. 2000;95:2651-2658.
10. van Dongen JJ, Langerak AW, Bruggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia. 2003;17:2257-2317.
11. Robertson LE, Huh YO, Butler JJ, et al. Response assessment in chronic lymphocytic leukemia after fludarabine plus prednisone: clinical, pathologic, immunophenotypic, and molecular analysis. Blood. 1992;80:29-36.
12. Esteve J, Villamor N, Colomer D, et al. Stem cell transplantation for chronic lymphocytic leukemia: different outcome after autologous and allogeneic transplantation and correlation with minimal residual disease status. Leukemia. 2001;15:445-451.
13. Rawstron AC, Kennedy B, Evans PA, et al. Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood. 2001;98:29-35.
14. Provan D, Bartlett-Pandite L, Zwicky C, et al. Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation. Blood. 1996;88:2228-2235.
15. Milligan DW, Fernandes S, Dasgupta R, et al. Results of the MRC pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses. Blood. 2005;105:397-404.
16. Pfitzner T, Engert A, Wittor H, et al. A real-time PCR assay for the quantification of residual malignant cells in B cell chronic lymphatic leukemia. Leukemia. 2000;14:754-766.
17. Bottcher S, Ritgen M, Pott C, et al. Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation. Leukemia. 2004;18:1637-1645.
18. Ritgen M, Bottcher S, Stilgenbauer S, et al. MRD kinetics can predict the time to relapse after autologous stem cell transplantation (SCT) in chronic lymphocytic leukemia (CLL) [abstract]. Blood. 2005;106:211-212. Abstract 714.
19. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87:4990-4997.
20. IgBlast. http://www.ncbi.nlm.nih.gov/igblast. Accessed August 25, 2005.
21. International ImMunoGeneTics (IMGT). http:// imgt.cines.fr:8104. Accessed August 25, 2005.
22. Bruggemann M, Droese J, Bolz I, et al. Improved assessment of minimal residual disease in B cell malignancies using fluorogenic consensus probes for real-time quantitative PCR. Leukemia. 2000;14:1419-1425.
23. Rawstron AC, Villamor N, Zehnder JL, et al. International standardized approach to molecular and flow cytometric residual disease monitoring in CLL [abstract]. Blood. 2004;104:8a. Abstract 15.
24. Kaplan E, Meier P. Non parametric estimations from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
25. Peto R, Pike M, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observations of each patient. Analysis and examples. Br J Cancer. 1977;35:1-39.
26. Dreger P, Ritgen M, Böttcher S, Schmitz N, Kneba M. The prognostic impact of minimal residual disease assessment after stem cell transplantation for chronic lymphocytic leukemia: is achievement of molecular remission worthwhile? Leukemia. 2005;19:1135-1138.
27. Montserrat E. Treatment of chronic lymphocytic leukemia: achieving minimal residual disease-negative status as a goal. J Clin Oncol. 2005;23:2884-2885.
28. Rawstron A, Villamor N, Ritgen M, et al. International standardized approach to molecular and flow cytometric residual disease monitoring in CLL [abstract]. Leuk Lymphoma. 2005;46(suppl 1):S100. Abstract 119.
29. Pavletic ZS, Arrowsmith ER, Bierman PJ, et al. Outcome of allogeneic stem cell transplantation for B cell chronic lymphocytic leukemia. Bone Marrow Transplant. 2000;25:717-722.
30. Horowitz MM, Montserrat E, Sobocinski K, et al. Hematopoietic stem cell transplantation for chronic lymphocytic leukemia [abstract]. Blood. 2000;96:522a. Abstract 2245.
31. Khouri IF, Keating MJ, Saliba RM, Champlin RE. Long-term follow-up of patients with CLL treated with allogeneic hematopoietic transplantation. Cytotherapy. 2002;4:217-221.
32. Doney KC, Chauncey T, Appelbaum FR. Allogeneic related donor hematopoietic stem cell transplantation for treatment of chronic lymphocytic leukemia. Bone Marrow Transplant. 2002;29:817-823.
33. Mattsson J, Uzunel M, Remberger M, et al. Minimal residual disease is common after allogeneic stem cell transplantation in patients with B cell chronic lymphocytic leukemia and may be controlled by graft-versus-host disease. Leukemia. 2000;14:247-254.
34. Ritgen M, Stilgenbauer S, von Neuhoff N, et al. Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy chain gene status: implications of minimal residual disease measurement with quantitative PCR. Blood. 2004;104:2600-2602.